The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
The use of metformin in type 1 diabetes: a systematic review of efficacy
Open accessAbstract
Aims/hypothesis As adding metformin to insulin therapy has been advocated in type 1 diabetes, we conducted a systematic review of published clinical trials and clinical trial databases to assess the effects on HbA(1c), weight, insulin-dose requirement and adverse effects.Methods We constructed evidence tables and fitted a fixed-effects model (inverse variance method) in order to assess heterogeneity between studies and give a crude measure of each overall treatment effect.Results Of 197 studies identified, nine involved randomisation with informed consent of patients with type 1 diabetes to metformin (vs placebo or comparator) in either a parallel or crossover design for at least 1 week. We noted marked heterogeneity in study design, drug dose, age of participants and length of follow-up. Metformin was associated with reductions in: (1) insulin-dose requirement (5.7-10.1 U/day in six of seven studies); (2) HbA(1c) (0.6-0.9% in four of seven studies); (3) weight (1.7-6.0 kg in three of six studies); and (4) total cholesterol (0.3-0.41 mmol/l in three of seven studies). Metformin was well tolerated, albeit with a trend towards increased hypoglycaemia. Formal estimates of combined effects from the five trials which reported appropriate data indicated a significant reduction in insulin dose (6.6 U/day, p < 0.001) but no significant reduction in HbA(1c) (absolute reduction 0.11%, p = 0.42). No reported trials included cardiovascular outcomes.Conclusions/interpretation Metformin reduces insulin-dose requirement in type 1 diabetes but it is unclear whether this is sustained beyond 1 year and whether there are benefits for cardiovascular and other key clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The addition of metformin to insulin therapy in type 1 diabetes is also associated with reductions in insulin-dose requirement and HbA1c levels [30,31].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [30]
In the citing paper
“There is some evidence that suggests improvement in metabolic control of poorly controlled adolescents with type 1 diabetes when metformin is added to insulin therapy.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [30]
In the citing paper
“Metformin has been shown to reduce insulin dose requirement (5.7–10.1 U/day), HbA1c (0.6–0.9%), weight (1.7–6.0 kg), and total cholesterol (0.3–0.41 mmol/l) [30].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
Towler, M. C., & Hardie, D. G. (2007) · Circulation Research · doi:10.1161/01.res.0000256090.42690.05 · Cited by 1,262
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Bolen, S. D., Feldman, L. S., Vassy, J. L., Wilson, L. M., Yeh, H., Marinopoulos, S. S., Wiley, C., Selvin, E., Wilson, R. F., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 817
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Diabetes Control and Complications Trial
Yue, D. K., Colagiuri, S., McElduff, A., & Silink, M. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb141357.x · Cited by 575
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell-Jones, D. L., & Khan, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 569
Purnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., & Brunzell, J. D. (1998) · JAMA · doi:10.1001/jama.280.2.140 · Cited by 469
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440 · cited 1×
“Recently published results from the Hyperinsulinaemia: the Outcome of its Metabolic Effects (HOME) trial have shown that metformin improves macrovascular outcomes in insulin-treated type 2 diabetes patients [ 71 ].”
ResultMorrow, V. A., Foufelle, F., Connell, J., Petrie, J. R., Gould, G. W., & Salt, I. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212831200 · Cited by 361
Self-citationWulffelé, M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01328.x · Cited by 359
CIPROFLOXACIN FOR CHOLANGITIS AFTER HEPATIC PORTOENTEROSTOMY
Houwen, R. H. J., Bijleveld, C. M. A., & de Vries-Hospers, H. G. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90663-5 · Cited by 309
Morris, A. D., Boyle, D. I., MacAlpine, R., Emslie-Smith, A. M., Jung, R. T., Newton, R. W., & MacDonald, T. M. (1997) · BMJ · doi:10.1136/bmj.315.7107.524 · Cited by 297
Soedamah-Muthu, S. S., Fuller, J. H., Mulnier, H. E., Raleigh, V. S., Lawrenson, R. A., & Colhoun, H. M. (2006) · Diabetologia · doi:10.1007/s00125-005-0120-4 · Cited by 240
Self-citationAMP‐activated protein kinase: role in metabolism and therapeutic implications
Schimmack, G., DeFronzo, R. A., & Musi, N. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00561.x · Cited by 231
Statins and diabetes – Authors' reply
Kearney, P. M., KEECH, A. C., Simes, R. J., Collins, R., & Baigent, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60761-8 · Cited by 185
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161
Moloney, F., Toomey, S., Noone, E., Nugent, A. P., Allan, B. B., Loscher, C. E., & Roche, H. M. (2007) · Diabetes · doi:10.2337/db06-0384 · Cited by 160
Metformin as an Adjunct Therapy in Adolescents With Type 1 Diabetes and Insulin Resistance
Hamilton, J. K., Cummings, E. A., Zdravković, V., Finegood, D. T., & Daneman, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.138 · Cited by 160
Jadhav, S., Ferrell, W., Greer, I. A., Petrie, J. R., Cobbe, S. M., & Sattar, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.088 · Cited by 157
Self-citationWright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
Mortality From Cerebrovascular Disease in a Cohort of 23 000 Patients With Insulin-Treated Diabetes
Laing, S. P., Swerdlow, A. J., Carpenter, L. M., Slater, S. D., Burden, A. C., Botha, J. L., Morris, A. D., Waugh, N. R., Gatling, W., Gale, E. A., et al. (2003) · Stroke · doi:10.1161/01.str.0000053843.03997.35 · Cited by 131
Särnblad, S., Kroon, M., & Åman, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490323 · Cited by 119
AMP‐ACTIVATED PROTEIN KINASE ACTIVATION AS A STRATEGY FOR PROTECTING VASCULAR ENDOTHELIAL FUNCTION
Zou, M., & Wu, Y. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04851.x · Cited by 116
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967 · Cited by 104
Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P. H., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P. R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003363 · Cited by 95
Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes
Pagano, G., Tagliaferro, V., Carta, Q., Caselle, M. T., Bozzo, C., Vitelli, F., Trovati, M., & Cocuzza, E. (1983) · Diabetologia · doi:10.1007/bf00251823 · Cited by 94
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes
Matsumoto, K., Sera, Y., Abe, Y., Tominaga, T., Yeki, Y., & Miyake, S. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.007 · Cited by 90
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients
Gin, H., Messerchmitt, C., Brottier, E., & Aubertin, J. (1985) · Metabolism · doi:10.1016/0026-0495(85)90139-8 · Cited by 82
Addressing insulin resistance in Type 1 diabetes
Pang, T. T. L., & Narendran, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02493.x · Cited by 81
Meyer, L., Böhme, P., Delbachian, I., Lehert, P., Cugnardey, N., Drouin, P., & Guerci, B. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2153 · Cited by 75
The Effect of Metformin in Overweight Patients with Type 1 Diabetes and Poor Metabolic Control
Jacobsen, I. B., Henriksen, J. E., & Beck‐Nielsen, H. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00380.x · Cited by 69
Visceral Obesity, Hepatic Lipase Activity, and Dyslipidemia in Type 1 Diabetes
Sibley, S. D., Palmer, J. P., Hirsch, I. B., & Brunzell, J. D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021693 · Cited by 68
Moon, R. J., Bascombe, L. ‐., & Holt, R. I. G. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00599.x · Cited by 63
The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes
Khan, A. S., McLoughney, C. R., & Ahmed, A. B. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01966.x · Cited by 59
Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents
Abdelghaffar, S., & Attia, A. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006691.pub2 · Cited by 58
Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics
Gin, H., Freyburger, G., Boisseau, M., & Aubertin, J. (1989) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(89)90058-2 · Cited by 55
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P. H., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P. R., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01079.x · Cited by 52
Gin, H., Slama, G., Weissbrodt, P., Poynard, T., Vexiau, P., Klein, J. C., & Tchobroutsky, G. (1982) · Diabetologia · doi:10.1007/bf00257727 · Cited by 36
The insulin-sparing effect of metformin in insulin-treated diabetic patients
Golay, A., Guillet-Dauphiné, N., Fendel, A., Juges, C., & Assal, J. P. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110510 · Cited by 35
DIMETHYLDIGUANIDE IN THE TREATMENT OF DIABETIC CHILDREN
Ferguson, A., de la Harpe, P. L., & Farquhar, J. (1961) · The Lancet · doi:10.1016/s0140-6736(61)92002-5 · Cited by 28
Urakami, T., Morimoto, S., Ōwada, M., & Harada, K. (2005) · Pediatrics International · doi:10.1111/j.1442-200x.2005.02075.x · Cited by 28
Gómez, R., Mokhashi, M. H., Rao, J. K., Vargas, A., Compton, T., McCarter, R., & Chalew, S. A. (2002) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2002.15.8.1147 · Cited by 26
Janssen, M., Rillaerts, E. G., & Leeuw, I. D. (1991) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(91)90067-4 · Cited by 25
Follow-up of Intensive Glucose Control in Type 2 Diabetes
Lund, S. S., Rossing, P. R., & Vaag, A. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc082275 · Cited by 22
Insulin Analogues in Children and Teens with Type 1 Diabetes: Advantages and Caveats
Rachmiel, M., Perlman, K., & Daneman, D. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.010 · Cited by 20
Metformin and Insulin: Is There a Role for Combination Therapy?
Daniel, J. R., & Hagmeyer, K. O. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100414 · Cited by 20
Rizkalla, S. W., Elgrably, F., Tchobroutsky, G., & Slama, G. (1986) · PubMed · Cited by 19
Failure of the biguanides to improve the control of unstable diabetes treated with insulin
Pirart, J. (1971) · Diabetologia · doi:10.1007/bf01211880 · Cited by 15
Safety Issues on Metformin Use
Aldasouqi, S. A., & Duick, D. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3356 · Cited by 15
Schatz, H., Winkler, G., Jonatha, E. M., & Ef, P. (1975) · PubMed · Cited by 15
Faichney, J. D., & Tate, P. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1655 · Cited by 14
Metformin and Insulin in Type 1 Diabetes
Meyer, L., & Guerci, B. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1655-a · Cited by 13
Coscelli, C., Palmari, V., Saccardi, F., Alpi, O., & Bonora, E. (1984) · Current Therapeutic Research · Cited by 13
The insulin sparing effect of metformin in insulin-treated diabetic patients.
Slama, G. (1991) · PubMed · Cited by 12
Potential Adjunctive Therapies in Adolescents with Type 1 Diabetes Mellitus
Jefferies, C., Hamilton, J. K., & Daneman, D. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403060-00002 · Cited by 11
[Metformin in the treatment of type 1 diabetics--a placebo controlled study].
Lacigová, S., Rušavý, Z., Jankovec, Z., & Kyselová, P. (2001) · PubMed · Cited by 9
Leblanc, H., Marre, M., Billault, B., & Passa, P. (1987) · PubMed · Cited by 7
Slama, G., Gin, H., Weissbrodt, P., Poynard, T., Vexiau, P., & Klein, J. C. (1981) · Diabetologia · Cited by 7
[Bedtime administration of metformin may reduce insulin requirements].
Ravina, A., & Minuchin, O. (1990) · PubMed · Cited by 4
Metformin use as an adjunct to insulin treatment in selected patients with type 1 diabetes mellitus
Gunton, J. E., & Twigg, S. M. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05374.x · Cited by 4
[Short-term and long-term effect of metformin in type 1 diabetics].
Lacigová, S., Rušavý, Z., Kyselová, P., Jankovec, Z., Kárová, R., & Cechurová, D. (2001) · PubMed · Cited by 3
[Value of metformin-insulin association in the treatment of insulin- dependent diabetes].
Fossati, P., Fontaine, P., & Beuscart, R. (1985) · PubMed · Cited by 1
Lestradet, H., Labram, C., Grégoire, J., BILLAUD, L., & Deschamps, I. (1966) · PubMed · Cited by 1
Flagged first, then by citations
2 of the 77 references couldn’t be matched to a known paper.
Research works printed but not linked: 11
- The National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes. National clinical guidelines for management in primary and secondary care (update). Royal College of Physicians, London
- International Diabetes Federation Clinical Guidelines Task Force (2005) Global guidelines for type 2 diabetes. International Diabetes Federation, Brussels
- Walravens PA, Chase PH, Klingensmith GJ, Ellison M, Cornell C, Monahan K (2000) Low dose metformin in adolescents with type 1 diabetes mellitus: a double blind, controlled study. Diabetes 49(Suppl 1):A128 (Abstract)
- Keen H, Collins ACG, Bending JJ (1987) Metformin increases response to insulin in type-1 (insulin-dependent) diabetes. Diabetologia 30:A538 (Abstract)
- Ahmed AE, Home PD, Marshall SM (2001) Effect of metformin in blood glucose control on people with type 1 diabetes. Diabetes 50(Suppl 2):A430 (Abstract)
- Melga P (1989) Usefulness and rationale of combined therapy with insulin and metformin in insulin-dependent diabetes (type I). G Ital Diabetol 9:247–253
- Tan AB, Bandyopadhyay S, Brake J, Weston PJ (2006) Effects of metformin in type 1 diabetes mellitus. Diab Med 23(Suppl 2):111 (Abstract)
- Alves C (2006) Metformin as an adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus. Revista Brasileira de Medicina 63:539–543
- Tagliaferro V, Pagano G, Carta Q, Vitelli F, Pisu E, Cocuzza E (1981) Insulin sparing effect of metformin on insulin requirement of IDDM assessed by artificial pancreas (Biostator Ames). Diabetologia 21:333 (Abstract)
- Meyer L, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B (1999) Continuous subcutaneous insulin infusion in type 1 diabetes: insulin-sparing effect of metformin. Diabetologia 42(Suppl 1):A226 (Abstract)
- Jacobsen PK, Lund SS, Tarnow L et al (2007) Impact of metformin treatment on glycaemic control and cardiovascular risk-factors in patients with poorly controlled type 1 diabetes (T1DM). Diabetologia 50(Suppl 1):S107 (Abstract)
Cited by
Sorted by citations
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 715
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 646
Metadata
- Authors
- Vella, S., Buetow, L., Royle, P., Livingstone, S., Colhoun, H. M., & Petrie, J. R.
- Affiliations
- University of Dundee (GB)
- University of Aberdeen (GB)
- Corresponding author
- Petrie, J. R.
- Venue
- Diabetologia
- Published
- 2010-01-08
- Volume
- 53
- Issue
- 5
- Pages
- 809-820
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1965620761
- Cited by
- 201
- References
- 77
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 12 · 2021: 8 · 2020: 14 · 2019: 10 · 2018: 17 · 2017: 27 · 2016: 21 · 2015: 19 · 2014: 12 · 2013: 13 · 2012: 11
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Pfizer
- University of Aberdeen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, type 1 diabetes, insulin dose reduction, HbA1c, body weight, total cholesterol, hypoglycemia, adverse effects
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 1, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Insulin, Metformin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
